Search clinical trials for: Inactivated trivalent influenza vaccine

Total 1415 results

National Institute of Allergy and Infectious Diseases...

Completed

Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4

Influenza | Influenza Immunisation | Avian Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy Adults

Orthomyxoviridae Infections | Pandemic Influenza | Influenza A Virus Infection

Belgium
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Preventing Flu in Children With Acute Lymphoblastic Leukemia

Leukemia | Infection

United States
Seqirus

Completed

Flucelvax (TIVc or QIVc) Pregnancy Registry

Pregnancy | Influenza, Human | Birth Defect

United States
Universitas Padjadjaran
Universiti Sains Malaysia; Biofarma

Completed

Effectiveness of Trivalent Influenza Vaccine (TIV) in Type 2 Diabetes Mellitus (T2DM) Patients With and Without Complications of Chronic Kidney Disease (CKD)

Diabetes Mellitus | Chronic Kidney Diseases | Vaccine Reaction | Influenza

Indonesia
Seqirus

Completed

A Study to Assess the Immunogenicity and Safety of a Trivalent Influenza Vaccine Containing the 2013/2014 Formulation of Enzira® Vaccine in Healthy Volunteers

Influenza, Human

United Kingdom
University of Michigan
American College of Allergy, Asthma and Immunology

Completed

Safe Administration of Flu Vaccine to Egg Allergic Children (SAFE)

Egg Allergy

United States
Seqirus
Novartis Vaccines

Completed

Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.

Influenza Virus

United States, Canada, Finland, Italy, Mexico, Philippines, Poland, Puerto Rico, Spain, Taiwan, Thailand
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

High-Dose Trivalent Influenza Vaccine in Inducing Immune Response Patients With Central Nervous System Tumors

Central Nervous System Neoplasm

United States
Richard Zimmerman MD
Centers for Disease Control and Prevention

Completed

Immunologic Response to FluMist vs. Flucelvax

Immune Response | Influenza, Human

United States
St. Louis University
MedImmune LLC

Completed

Live Attenuated Influenza Vaccine (LAIV) Versus Trivalent Inactivated Influenza Vaccine in Healthy Adults 18-49 Years

Influenza
University of Rochester

Terminated

Study of Live, Attenuated Influenza Vaccination in Preterm and Full-Term Infants

Influenza
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of 2 Formulations of an Intramuscular A/H5N1 Pandemic Influenza Vaccine in Children

Influenza | Orthomyxoviridae Infections | Influenza A Virus Infection

Thailand
Vanderbilt University Medical Center
Duke University; Centers for Disease Control and Prevention; Children's Hospital...

Completed

Safety of LAIV4 in Children With Asthma

Vaccine Adverse Reaction | Vaccine Reaction | Asthma | Influenza | Asthma in Children | Wheezing

United States
Memorial Sloan Kettering Cancer Center

Completed

Prospective Trial of Vaccine Responses Against Pneumococcus and Influenza in Adult Cancer Patients 65 Years of Age and Older

Breast Cancer | Lung Cancer | Prostate Cancer

United States
National Centre for Epidemiology, Hungary
Netherlands Vaccine Institute; National Public Health Institute, Finland

Unknown

Comparison of the Cellular and the Humoral Immunogenicity, Safety of Different Trivalent Influenza Vaccines (FLUSECUOEKH1)

Healthy Volunteers

Hungary
Novartis Vaccines

Completed

A Post-marketing Study to Monitor the Safety of a MF59-adjuvanted Influenza Vaccine Administered in Korean Subjects Aged 65 Years or Older

Influenza

Korea, Republic of
Sinovac Biotech (Colombia) S.A.S.
Sinovac Life Sciences Co., Ltd.

Not yet recruiting

Immunogenicity and Safety Study of One Booster Dose of Trivalent COVID-19 Vaccine (Vero Cell), Inactivated

COVID-19

Colombia
Saad Jamshed MD
Sanofi

Completed

Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving Chemotherapy (IMMUNE)

Cancer | Influenza Viral Infections

United States
Ology Bioservices

Completed

Safety and Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived)

Influenza

Austria, Germany, Poland
Emory University
National Cancer Institute (NCI); Sanofi; National Institutes of Health (NIH)

Completed

Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders

Plasma Cell Neoplasm

United States
Green Cross Corporation

Completed

Safety, Tolerability, and Immunogenicity of GC3106 (Quadrivalent Cell-culture Based Influenza Vaccine)

Influenza

Korea, Republic of
GlaxoSmithKline

Completed

Immunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years Old

Influenza

Korea, Republic of
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Trivalent Influenza Vaccine in Preventing Flu in Patients With Central Nervous System Tumors

Central Nervous System Neoplasm

United States
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Inactivated Swine-Origin A/H1N1 Influenza Vaccines in Healthy European Subjects Aged 3 to 17 Years

Influenza | Swine-origin A/H1N1 Influenza

Finland
MedImmune LLC
AstraZeneca

Completed

Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults for the 2015-2016 Season (FluMist)

Healthy | Influenza

United States
MedImmune LLC
AstraZeneca

Completed

Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

Healthy | Influenza

United States
Universitaire Ziekenhuizen KU Leuven

Completed

Influenza Vaccination in Hemodialysis Patients and Renal Transplant Recipients

Hemodialysis | Renal Transplantation

Belgium
University of Witwatersrand, South Africa
Bill and Melinda Gates Foundation

Completed

Immunogenicity and Safety of Trivalent Influenza Vaccine in Pregnant and Nonpregnant HIV Uninfected Women

Influenza

South Africa
National Institute of Allergy and Infectious Diseases...

Completed

Trivalent rHA Dose Escalation Study in Elderly Subjects

Influenza

United States
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of Trivalent Split Influenza Vaccine Using the Strain Composition 2007/2008

Seasonal Influenza | Vaccine

Germany
Green Cross Corporation

Completed

A Phase I/IIa Study of GC3110A (Quadrivalent Influenza Vaccine)

Influenza

Korea, Republic of
St. Petersburg Research Institute of Vaccines and...

Completed

Tolerability, Safety and Immunogenicity Trial of the Flu-M® Inactivated Vaccine in Volunteers Aged 18 to 60 Years

Influenza | Flu, Human

Russian Federation
Sanofi Pasteur, a Sanofi Company

Completed

Study of Sanofi Pasteur's Intradermal Influenza Vaccine (IDflu™) in Adults and Elderly in Korea

Influenza

Korea, Republic of
University of Sao Paulo General Hospital
D'Antonio Consultants International, Inc.; Sao Paulo, Secretaria de Estado...

Unknown

Assessment of Needle-free Disposable-syringe Jet Injector (DSJI) ID Dose-sparing of Pandemic A H1N1 Influenza Vaccine

Influenza

Brazil
Solvay Pharmaceuticals

Withdrawn

Annual Study to Investigate Inactivated Virosomal Influenza Vaccine for the 2006/2007 Influenza Season in Europe.

Healthy Volunteers

Germany
Solvay Pharmaceuticals

Completed

Annual Study to Investigate Influenza Vaccine Due to New Virus Strains for the 2007/2008 Influenza Season in Europe

Healthy Volunteers

Belgium, Germany
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age (QHD04)

Influenza

United States, Canada
Il-Yang Pharm. Co., Ltd.

Completed

Study to Evaluate the Immunogenicity and Safety of 'IL-YANG Quadrivalent Influenza Vaccine Inj.'

Influenza
Johns Hopkins Bloomberg School of Public Health
Columbia University; Sanofi Pasteur, a Sanofi Company; Institute of Epidemiology... and other collaborators

Completed

Pregnancy, Arsenic and Immune Response (PAIR)

Influenza | Vaccine Response Impaired | Micronutrient Deficiency | Arsenic--Toxicology | Immunologic Disorders Complicating Pregnancy

Bangladesh
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Safety of and Immune Response to Two Influenza Vaccines in HIV Infected Children and Adolescents

HIV Infections | Influenza

United States, Puerto Rico
Novartis Vaccines

Completed

Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects

Influenza | Seasonal Influenza | Human Influenza | Influenza Due to Unspecified Influenza Virus

Belgium
Monroe County Department of Public Health
University of Rochester

Completed

School Influenza Vaccine vs Standard of Care With Nested Trial of 2 Parent Notification Intensities (MCSkipp)

Influenza | Vaccination | School Health | Immunizations

United States
Duke University
Boston Medical Center; Centers for Disease Control and Prevention; Children's...

Completed

Safety of RIV4 Versus IIV4 in Pregnant Women

Safety | Birth Outcomes | Adverse Event Following Immunisation

United States
Adimmune Corporation

Completed

Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2012-2013, in Non-Elderly Adult and Elderly Subjects

Influenza

Taiwan
Fluart Innovative Vaccine Ltd, Hungary

Completed

Immunogenicity and Tolerability Study of FluvalAB FL-K-004 Trivalent Influenza Vaccine

Influenza

Hungary
Duke University
Centers for Disease Control and Prevention; Children's Hospital Medical Center...

Completed

Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women (Tdap/IIV)

Pregnancy

United States
Kaiser Permanente
Seqirus

Recruiting

Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years

Influenza | Community-acquired Pneumonia | Cardiovascular Events

United States
Seqirus

Completed

A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years

Influenza, Human

United States
Sinovac Biotech Co., Ltd

Completed

Sinovac, Pandemic Influenza A/H1N1 Vaccine in 6 to 35 Months Infants

Influenza

China

Search clinical trials for: Inactivated trivalent influenza vaccine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations